Does the antisecretory peptide AF-16 reduce lung oedema in experimental ARDS?

  • Annelie Barrueta Tenhunen Hedenstierna Laboratory, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden http://orcid.org/0000-0003-0815-375X
  • Fabrizia Massaro Hedenstierna Laboratory, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden; Cardiac Anesthesia and Intensive Care, Anthea Hospital, GVM Care & Research, Bari, Italy
  • Hans Arne Hansson Institute of Biomedicine, University of Gothenburg, G€oteborg, Sweden
  • Ricardo Feinstein Department of Pathology and Wildlife Diseases, National Veterinary Institute, Uppsala, Sweden
  • Anders Larsson Department of Medical Sciences, Uppsala University, Uppsala, Sweden http://orcid.org/0000-0002-0702-8343
  • Anders Larsson Hedenstierna Laboratory, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden
  • Gaetano Perchiazzi Hedenstierna Laboratory, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden http://orcid.org/0000-0001-6834-6399
Keywords: AF-16 antisecretory factor, ARDS, extravascular lung water, pulmonary oedema

Abstract

Background: Acute respiratory distress syndrome (ARDS) is an acute inflammatory condition with pulmonary capillary leakage and lung oedema formation. There is currently no pharmacologic treatment for the condition. The antisecretory peptide AF-16 reduces oedema in experimental traumatic brain injury. In this study, we tested AF-16 in an experimental porcine model of ARDS.

Methods: Under surgical anaesthesia 12 piglets were subjected to lung lavage followed by 2 hours of injurious ventilation. Every hour for 4 hours, measurements of extravascular lung water (EVLW), mechanics of the respiratory system, and hemodynamics were obtained.

Results: There was a statistically significant (p = 0.006, two-way ANOVA) reduction of EVLW in the AF-16 group compared with controls. However, this was not mirrored in any improvement in the wet-to-dry ratio of lung tissue samples, histology, inflammatory markers, lung mechanics, or gas exchange.

Conclusions: This pilot study suggests that AF-16 might improve oedema resolution as indicated by a reduction in EVLW in experimental ARDS.

Downloads

Download data is not yet available.
Published
2019-11-08
How to Cite
Barrueta Tenhunen, A., Massaro, F., Hansson, H. A., Feinstein, R., Larsson, A., Larsson, A., & Perchiazzi, G. (2019). Does the antisecretory peptide AF-16 reduce lung oedema in experimental ARDS?. Upsala Journal of Medical Sciences, 124(4), 246–253. https://doi.org/10.1080/03009734.2019.1685029
Section
Original Articles